Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by TriSalus Life Sciences
TriSalus Reports Q2 2024 Financial Results and Business Update
August 15, 2024
From
TriSalus Life Sciences
Via
Business Wire
Tickers
TLSI
TriSalus Life Sciences to Host Second Quarter 2024 Financial Results Conference Call
August 01, 2024
From
TriSalus Life Sciences
Via
Business Wire
Tickers
TLSI
TriSalus Life Sciences Announces Completion of Exchange Offer and Consent Solicitation
July 01, 2024
From
TriSalus Life Sciences
Via
Business Wire
Tickers
TLSI
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants
June 26, 2024
From
TriSalus Life Sciences
Via
Business Wire
Tickers
TLSI
TriSalus Life Sciences Highlights Clinical Data from Phase 1b PERIO-02 Trial, Studying Delivery of Nelitolimod via Pressure-Enabled Drug Delivery in Patients with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma at 2024 ASCO Annual Meeting
June 03, 2024
From
TriSalus Life Sciences
Via
Business Wire
Tickers
TLSI
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants
May 24, 2024
From
TriSalus Life Sciences
Via
Business Wire
Tickers
TLSI
TriSalus Reports Q1 2024 Financial Results and Business Update
May 15, 2024
From
TriSalus Life Sciences
Via
Business Wire
Tickers
TLSI
TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors
May 07, 2024
From
TriSalus Life Sciences
Via
Business Wire
Tickers
TLSI
TriSalus Life Sciences to Host First Quarter 2024 Financial Results Conference Call
May 06, 2024
From
TriSalus Life Sciences
Via
Business Wire
Tickers
TLSI
TriSalus Life Sciences Secures up to $50 million of Debt Financing with OrbiMed to Support TriNav® Infusion System Growth Initiatives
April 30, 2024
From
TriSalus Life Sciences
Via
Business Wire
Tickers
TLSI
TriSalus Reports Q4 and Full Year 2023 Financial Results and Business Update
April 01, 2024
From
TriSalus Life Sciences
Via
Business Wire
Tickers
TLSI
TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting
March 26, 2024
From
TriSalus Life Sciences
Via
Business Wire
Tickers
TLSI
TriSalus Life Sciences Announces Oral Presentations at the Upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting
March 21, 2024
From
TriSalus Life Sciences
Via
Business Wire
Tickers
TLSI
TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association’s Adopted Name Council for “Nelitolimod” as the Nonproprietary Drug Name for SD-101
March 07, 2024
From
TriSalus Life Sciences
Via
Business Wire
Tickers
TLSI
TriSalus Life Sciences Announces Real-World Data Demonstrating the Ability of TriNav® to Successfully Treat Patients with Higher Disease Burden and to Improve Delivery of Therapeutics to Liver Tumors
February 29, 2024
From
TriSalus Life Sciences
Via
Business Wire
Tickers
TLSI
TriSalus Life Sciences Announces Late Breaker and Additional Data Presentations on Liver Metastases and Pancreatic Cancer at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
October 25, 2023
From
TriSalus Life Sciences
Via
Business Wire
Tickers
TLSI
TriSalus Life Sciences Appoints Jodi Devlin as President of TriSalus Therapeutics
September 06, 2023
From
TriSalus Life Sciences
Via
Business Wire
Tickers
TLSI
TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation
August 10, 2023
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting
June 12, 2023
From
TriSalus Life Sciences
Via
Business Wire
Tickers
MTAC
TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases
April 20, 2023
From
TriSalus Life Sciences
Via
Business Wire
Tickers
MTAC
TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) Clinical Trial Progress and Pre-clinical Research Developments
December 15, 2022
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 Clinical Studies
November 21, 2022
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences to Become Publicly Traded Through Merger With MedTech Acquisition Corporation
November 14, 2022
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Provides Update on Development of Immunotherapy Platform Approach for Liver and Pancreatic Tumors
June 22, 2022
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Enrolls First Patient in PERIO-02 Clinical Trial, Studying the Delivery of SD-101 via Pressure-Enabled Drug Delivery in Adults with Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
May 10, 2022
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Expands Clinical Executive Team and Scientific Advisors in Support of Company’s Focus to Overcome Liver and Pancreatic Cancer Treatment Barriers and Enable More Patients to Benefit From Immunotherapy
February 10, 2022
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces Collaboration with the University of Colorado Anschutz Medical Campus to Advance Research on Innovative Immuno-oncology Treatments for Patients with Liver and Pancreatic Tumors
January 20, 2022
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Appoints Industry Expert Sean Murphy to Board of Directors
October 05, 2021
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Announces First Patient Enrolled in PERIO-01 Clinical Trial to Evaluate Delivery of SD-101 via Pressure-Enabled Drug Delivery in Uveal Melanoma Liver Metastases
September 07, 2021
From
TriSalus Life Sciences
Via
Business Wire
TriSalus Life Sciences Presents Data at American Association of Cancer Research Showing Reduced Liver Tumor Burden from Toll-Like Receptor Agonists
April 14, 2021
From
TriSalus Life Sciences
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.